Table 1. Distribution of the characteristics of prostate cancer in patients presented at a participating hospital in Central Sudan (n = 453).
| Characteristics | Distribution |
|---|---|
| Stage at diagnosis | |
| I | 2 (0.4%) |
| II | 3 (0.7%) |
| III | 122 (27%) |
| IV | 326 (72%) |
| Primary clinical presentation | |
| Lower urinary tract symptoms | 243 (54%) |
| Bladder outlet obstruction | 82 (18%) |
| Urine retention | 61 (14%) |
| Unilateral ureteral obstruction | 21 (5%) |
| Bilateral ureteral obstruction | 20 (4%) |
| Others | 26 (6%) |
| Classification | |
| Organ confined | 9 (2%) |
| Locally advanced | 205 (45%) |
| Castration resistance | 31 (7%) |
| Distant metastasis | 208 (46%) |
| Gleason score | |
| 2–6 | 67 (16%) |
| 7 | 113 (27%) |
| 8–10 | 244 (58%) |
| Prostate-specific antigen level at diagnosis (ng/mL) | |
| <4 | 40 (9%) |
| 4–20 | 62 (14%) |
| 21–50 | 53 (12%) |
| 51–100 | 61 (14%) |
| 101–200 | 162 (36%) |
| >200 | 75 (17%) |
| Treatmenta | |
| Hormonal only | 315 (70%) |
| Radiotherapy only | 14 (3%) |
| Hormonal + Radiotherapy | 123 (27%) |
| Vital status at the end of follow-upb | |
| Alive | 251 (55%) |
| Dead | 202 (45%) |
a
One patient reported that chemotherapy was excluded.
b
Length of follow-up ranging from 0 to 79 months, with a median of 24 months.